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Abstract
Objective: Higher than expected pregnancy rates have been observed in HIV related clinical trials in Sub-Saharan Africa. We
designed a qualitative study to explore the factors contributing to high pregnancy rates among participants in two HIV
clinical trials in Sub-Saharan Africa.
Methods: Female and male participants enrolled in one of two clinical HIV trials in south-west Uganda were approached.
The trials were a phase III microbicide efficacy trial among HIV negative women using vaginal gel (MDP); and a trial of
primary prevention prophylaxis for invasive cryptococcal disease using fluconazole among HIV infected men and women in
Uganda (CRYPTOPRO). 14 focus group discussions and 8 in-depth interviews were conducted with HIV positive and
negative women and their male partners over a six month period. Areas explored were their experiences about why and
when one should get pregnant, factors affecting use of contraceptives, HIV status disclosure and trial product use.
Results: All respondents acknowledged being advised of the importance of avoiding pregnancy during the trial. Factors
reported to contribute to pregnancy included; trust that the investigational product (oral capsules/vaginal gel) would not
harm the baby, need for children, side effects that led to inconsistent contraceptive use, low acceptance of condom use
among male partners. Attitudes towards getting pregnant are fluid within couples over time and the trials often last for
more than a year. Researchers need to account for high pregnancy rates in their sample size calculations, and consider lesser
used female initiated contraceptive options e.g. diaphragm or female condoms. In long clinical trials where there is a high
fetal or maternal risk due to investigational product, researchers and ethics committees should consider a review of
participants contraceptive needs/pregnancy desire review after a fixed period, as need for children, partners and health
status of participants may alter over time.
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Introduction
Sub Saharan Africa has the highest fertility rate of any world
region, at 5.77 children born per woman [1]. In Uganda the
fertility rate in 2009 was 6.7 children born per woman [2]. Whilst
contraceptive use is increasing by 0.7% per year across the
continent, many women have difficulties in accessing contracep-
tives; it is estimated that 41% of women in Uganda have an unmet
need for contraception [3].
In couples affected by HIV desire for pregnancy and
contraceptive needs are complex issues [4]. A Ugandan study of
desire for children and pregnancy risk in HIV infected men and
women showed that 27% of men reported wanting more children.
Of the 73% of men who reported that they did not want more
children 33% still practiced ‘‘risky’’ sexual behaviour (defined as
sex without using condoms) [5]. Another study in Uganda showed
that 59% HIV positive women in HIV sero-discordant couples
desired to get pregnant [6]. Among women on antiretroviral
therapy in rural Uganda followed for 2.4 years, only 7% of 711
women reported wanting more children at any time point,
however by the end of the follow up period 16.9% women had
become pregnant [7]. In Rwanda and Zambia, contraceptive
knowledge, use and concerns amongst HIV discordant couples
were examined and despite high levels of knowledge of contra-
ception 90%, use of contraceptive methods remains relatively low
(at between 30–59%) [8].
In clinical research, pregnancy is an exclusion criterion for
participation in most trials [9,10]. Often becoming pregnant once
enrolled in a trial is classified as an adverse event and leads to
withdrawal of participation from the trial. A higher than expected
pregnancy rate within a trial may have an impact on the analysis
as the withdrawal of participants may affect the statistical power of
a study. Therefore, there has been a lot of interest in observations
that HIV clinical trials involving women of reproductive age in
Sub Saharan Africa have high pregnancy rates. In many HIV
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microbicide gel studies, for example, the researchers undertake
continuous education and promotion of consistent use of condoms
for HIV prevention, and condoms for contraception are often
supplemented with the addition of a second hormonal contracep-
tion. Despite these measures pregnancy rates of 21–76 pregnancies
per 100 person years have been reported in these trials [11–13].
These observations have led to work on assessment of
contraceptive use in microbicide and vaccine study participants
but there is little depth analysis on the socio-cultural factors
determining pregnancy in women during HIV clinical trials in
Africa.
Between 2003 and 2007 two HIV related clinical trials took
place in Masaka district in South Western Uganda. One study was
the primary prophylaxis of cryptococcal disease using fluconazole
in HIV infected Ugandan adults (CRYPTOPRO –
ISRCTN76481259). The second trial was the Masaka site of
Microbicide Development Programme trial, an international
multi-center phase III to evaluate the efficacy and safety of 0.5%
and 2% PRO 2000/5 gel compared to a placebo for the
prevention of vaginally acquired HIV infection (MDP-ISRCTN
64716212). The methodologies of these have been previously
published [14,15]; in summary the CRYPTOPRO trial included
both HIV positive women and men (above 18 years of age),
whereas the MDP trial enrolled sero-discordant couples, com-
prised of HIV negative women (above 18 years of age) and HIV
positive men. In CRYPTOPRO participants were followed up for
a period of up to 24 months and 5.4 % (N=54) of 982 HIV
positive women became pregnant. There were 21 live births and
there was no evidence of fluconazole related abnormalities in live
born babies [14]. In MDP the participants were followed up for a
maximum period of 24 months and the pregnancy rate in this
study was 16.3% (N=137) of the 840 HIV negative women. In
SSA HIV positive women with low CD4 counts have reduced
fertility, as compared to HIV negative women [16] therefore the
difference in pregnancy rates between these group is not
surprising, but both trials experienced a higher than expected
pregnancy rate.
In this paper we present a study designed to investigate issues
surrounding attitudes, knowledge and feelings about the main
contributing factors leading to pregnancy or avoidance of
pregnancy of participants in these two trials. This study was
designed to evaluate views of both HIV positive and negative
women enrolled in the trials and also their male partners.
Methods
CRYPTOPRO and MDP Trial Consent Process with respect
to pregnancy and contraception
Prior to enrolment in CRYPTOPRO, female and male
participants were counselled by trained counsellors about the
possible but unlikely risk of fluconazole causing congenital
abnormalities. In the MDP trial couples were enrolled together
and both were counselled that the effects of gel on pregnancy are
not known and gel did not act as a contraceptive method. In both
trials at enrolment and at every appointment (every 8 weeks for
CRYPTOPRO and every 4 weeks for MDP) the women
underwent a pregnancy test, were counselled about avoiding
pregnancy and were offered various contraceptive methods. Those
who had a positive pregnancy test on either study were withdrawn
from trial products. Pregnant women were given an appointment
by an independent physician during pregnancy and infants were
seen by a paediatrician. Follow up continued until after the end of
their pregnancy.
Recruitment for the pregnancy study
HIV positive female participants in the CRYPTOPRO trial and
HIV negative female participants in the MDP trial were invited to
join this study. Female participants who were currently pregnant
at the time of the pregnancy study or who had completed a
pregnancy during the trials were identified through the CRYP-
TOPRO and MDP databases. These trials recruited from the
whole Masaka region, which is a large rural region of South West
Uganda, with poor infrastructure, and so we chose purposive
sampling. We then identified non-pregnant female MDP and
CRYPTOPRO participants living within similar vicinity as the
pregnant women, as additional potential enrolees to the study. The
female participants were approached at their homes (consent for
this had been given at trial enrolment) and given brief information
about the pregnancy study. They were then asked to attend a
specific appointment where they were given more detailed
information about the study, their questions were answered by
the study team and those who agreed to participate gave written
informed consent for inclusion in the pregnancy study. Of 130
MDP and CRYPTOPRO trial participants approached, 94 were
enrolled in the sub study. Those who did not take part had either
moved, were not available at time of study or were unable to make
it for the FGDs. Two female participants refused consent. The
distribution of participants and focus groups are shown in figure 1.
In order to recruit men for the study women who enrolled in the
pregnancy study were asked if we could approach their male
partners for inclusion for this study. 21 male partners agreed to
take part in the study; these were HIV positive partners of women
in the MDP study and either HIV positive or HIV negative
partners of those in the CRYPTOPRO trial. Those who agreed to
participate after an information session about the study completed
the informed consent process.
Data collection
Women and male volunteers were invited to participate in focus
group discussions (FGDs N=14; 23 male and 53 female
participants) and in-depth interviews (IDIs N= 8; 5 female, 2 of
whom were still pregnant and 3 had completed pregnancy and 3
HIV positive male partners from MDP with pregnant partners).
The focus groups had between 5–10 participants and on average
there were six participants in each FGD. The FGDs were
conducted in communities where participants agreed to meet at
specified venues. IDIs were conducted at the volunteer’s home in
privacy. Data collection for this study took 6months (September
2008 to February 2009) to complete. The FGD and IDIs were
conducted in the local language of Luganda, by trained
interviewers using semi-structured guides. The interviewers were
trained and had experience counselling in HIV, contraception and
training and experience in qualitative research methods. They had
no prior relationship to the participants. The main topics discussed
during the FGDs and IDIs were; perceptions about pregnancy,
reasons for becoming pregnant, contraceptive use, partner
involvement, and issues of consenting to the trials and beliefs
about the trial products (gel and fluconazole). The sample size was
not predetermined but data was collected with subsequent new
participants until there was no new information emerging (but
repeat interviews with individuals were not performed).
All collected data was audio recorded and later transcribed into
English and coded under the main themes and topics of the study.
Comparison of responses from the women who got pregnant and
those who never got pregnant were made. Comparison of the
responses from male whose partners got pregnant and those whose
partners didn’t get pregnant were also made. The different
responses from the different groups were categorised and analysed
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by 2 social scientists (AS, SN) and a 3rd researcher (RPR) with the
support of the qualitative data analysis software Nvivo 2.
Ethics Statement
Participants gave written or, if illiterate, witnessed verbal
consent (documented on the consent form) to involvement in the
study.The study and consent process was approved by the
institutional regulatory body of Uganda Virus Research Institute
ref; GC/127/07/08/05 and by the Uganda National Council of
Science and Technology ref: SS2134.
Results
The results of this sub-study are shared according to the main
themes that came out of the discussions and in-depth interviews
with the participants. We have attempted to analyse the issues
according to HIV status and gender issues, including complexities
around discordant couples.
Did the participants understand the consent process?
All MDP and CRYPTOPRO participants who were inter-
viewed in this study acknowledged the importance of avoiding
pregnancy during the trial. Most women mentioned that they had
been given pregnancy counselling and mentioned information
sheets given to them to explain that the products in the trials had
never been tested on pregnant women and that becoming
pregnant during the trial would lead to discontinuation of
participation. The women interviewed who became pregnant
during the MDP trial reported that they did not think the gel
would affect their unborn babies and this was reinforced by
normal pregnancy outcomes in themselves and in their colleagues:
‘‘I think that the drug was okay because for me I used it while pregnant and
it did not affect me. I took a full month taking it because I was not convinced
that I was pregnant. –Female HIV+ve with completed pregnancy
(CRYPTOPRO).
‘‘At this moment we have no proof of whether the drug deforms a baby but
the woman was in the trial and she gave birth to a full child without any
deformation’’ Female HIV +ve not pregnant (CRYPTOPRO).
Whilst all participants interviewed understood the consent
process and the majority of women stated that they had no
intention of getting pregnant while on the trial, one couple in the
MDP trial admitted that although they consented to be in the trial
they were still planning to get pregnant:
‘‘We had a plan; her pregnancy was not by mistake’’ HIV+ve male with
female HIV –ve pregnant partner (MDP).
What social and cultural factors surrounding fertility
contributed to the couple’s use of contraception and
fertility outcomes?
Trial participants and their partners from both genders and
sero-status (HIV positive and HIV negative men and women)
expressed strong desires to have children (if childless), a desire for a
certain number of children and for children of a particular sex.
These desires overruled the advice given by the study teams about
the risk of pregnancy. Additionally many expressed that fertility
desires also outweighed the risk of HIV transmission/acquisition:
‘‘I would want my partner to give birth to some more children for me to add
on because now I have one boy and girl so I would want my partner … to have
another boy’’ Male partner of female HIV+ve not pregnant
(CRYPTOPRO).
‘‘The man had only two children and we had total disagreement between us
about using condoms, even after l was found HIV positive, so I eventually got
pregnant’’ Female HIV +ve with completed pregnancy (MDP).
Beliefs of other family members and wider cultural beliefs also
played a role in the desire to have another child:
‘‘When l told my mother that l was using family planning methods, she
advised me to have another child because my last pregnancy l bore twins. She
said a woman must have another child after the twins, otherwise the twins will
Figure 1. The distribution of participants in the study.
doi:10.1371/journal.pone.0073556.g001
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be cursed and get problems’’. Female HIV-ve completed pregnancy
(MDP).
In the MDP trial HIV negative women were enrolled with their
HIV positive male partners and the men were aware of gel use by
the women. Anxieties were expressed by HIV positive men in this
trial about the fear of relationship breakdown due to the pressure
of a being a discordant couple. Becoming pregnant was seen as a
mitigating factor to relationship breakdown in some couples:
‘‘Another thing is that you may have just got your partner and you may have
got her with difficulty, and you don’t have a child, so… you want her to give
birth’’ HIV+ve male with female HIV –ve pregnant partner
(MDP).
In contrast to the MDP trial all participants in the CRYPTO-
PRO trial were HIV positive, and often in very poor health with
low CD4 counts at trial enrolment. Those who started on
antiretroviral therapy (ART) consequently had an improvement in
their health. This is likely to have increased their fertility [16], and
also these improvements in health encouraged both female
participants and their male partners to consider pregnancy whilst
still within the trials:
‘‘When these men see that you have been taking ARV’s and are looking
healthy, they start telling you to have babies’’ Female HIV+ve completed
pregnancy (CRYPTOPRO).
However, some participants expressed that other community
members have negative views about pregnancy in those who are
known to be HIV positive:
‘‘When I got pregnant people were surprised and it is embarrassing for us
because they see the man as a dead man’’ Female HIV-ve completed
pregnancy (MDP).
HIV positive women in the CRYPTOPRO trial explained that
they did not access contraception if they were not with a regular
partner, so may have unprotected sex with a casual or infrequent
partner. Stigma surrounding HIV status contributed to lack of
disclosure; some explained that they could not discuss contracep-
tion with their partner, as they had not disclosed their serostatus:
‘‘He does not know about my HIV serostatus and l do everything secretly
because we do not live together all the time’’ Female HIV+ve completed
pregnancy (CRYPTOPRO).
How did women’s experiences and beliefs surrounding
contraceptive methods affect adherence to
contraception?
Negative views and experiences. In both trials the main
methods of contraception reported by the women were the
progesterone injection, hormonal contraceptive pills, intrauterine
contraceptive devices (IUCD) and condoms. Most women
reported that they got their contraceptive supplies from the trial
teams, or from other health care facilities. All of the women
interviewed acknowledged that they understood the need for
contraceptives.
Many women in the trials suffered from well documented and
frequently reported side effects of hormonal contraception. These
included irregular or longer periods, ammenorrhoea and weight
gain. Some women persevered and another method hormonal
contraception, which suited them better:
‘‘I used to use injectable (Depo-Provera) but l got so fat we started using
condoms but one time it got torn’’ Female HIV-ve completed pregnancy
(MDP).
Use and knowledge of traditional methods or ‘‘herbs’ was
frequently mentioned, either as an alternative to hormonal
contraception, with less side effects, or as an adjunct to condoms
alone. Use and knowledge of these medicines was from other
female community members:
‘‘I got the injection from the clinic…but I got side effects due to that
injection. That’s why they directed me to get some local herbs….but I don’t
how it failed and I got pregnant again’’ Female HIV +ve pregnant
(CRYPTOPRO).
Women reported that men were unwilling to use condoms, or
inconsistently used them. The reasons for this were multifactorial
and included alcohol use, desire for more children, or lack of
enjoyment. Some women believed that men had even purposefully
damaged a condom in order for their partners to become
pregnant:
‘‘He either did not put on the condom which I didn’t realize or he pierced it’’
Female HIV-ve with completed pregnancy (MDP).
Positive views and experiences. Whilst a number of
women in the trials had poor experiences with contraception,
there were many women who had positive experiences with family
planning, and who were prepared to make considerable efforts to
avoid pregnancy. Some women reported saving money for
transport to the clinic to refill/renew their contraceptives. They
felt that they had to take this responsibility themselves, and relying
on partners to give them money was not sufficient. Women also
acknowledged that dual methods (condom plus one other) of
contraception were both more effective than a single method, and
gave greater reassurance if a woman was anxious to avoid
pregnancy:
‘‘At first I used pills but failed but now I use two methods; injections and
condoms and the reason why I use two is because sometimes I may fail to get a
condom and I put myself at risk but when the injection is there then am not
worried’’ Female HIV –ve not pregnant(MDP).
Some women who were keen to avoid pregnancy against their
partners’ wishes used contraception secretly:
‘‘l did not tell him at first because he did not like the contraceptive pills so l
used them secretly but when they started making me sick l had to tell him’’
Female HIV –ve completed pregnancy (MDP).
Both positive and negative views of women regarding contra-
ception as outlined above were similar in both the HIV positive
CRYPTO participants and HIV negative MDP female partici-
pants. However, an additional issues raised by participants in the
CRYPTO trial was a correct acknowledgement that hormonal
contraception may not be as effective in preventing pregnancy in
HIV positive women those taking ART. This led to some not
trusting the hormonal contraception, and being unwilling to
continue use of these methods.
The male perspective on family planning in the context
of clinical trials
Male partners were aware of various contraceptive methods, but
the responsibility of accessing hormonal contraceptives and using
them appropriately was deemed to be the responsibility of the
women. The men views on contraception were mainly limited to
the advantages and, more commonly, disadvantages of condom
use, as these seemed to have a most significant impact on their
sexual experiences. The men appear to be most frequent decision
makers when it comes to condom use:
‘‘The truth is that with a condom sometimes you don’t get enjoyment
although we try to use them because there is something that we are preventing
but they are difficult since it is like eating tasteless food’’ Male with female
HIV+ve not pregnant partner (CRYPTOPRO).
When hormonal contraception by men was discussed, it was
mainly in relation to avoiding condom use:
‘‘Another thing is that the injection is better than a condom because she
receives the injection for three months…… you may leave them at home and
when you come back there you go [can have sex]’’ Male HIV+ve with
female HIV –ve pregnant partner (MDP).
Pregnancy in HIV Clinical Trials in Africa
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Facing the consequences –thoughts on unplanned
pregnancy
The women reported that they were not happy when the gel or
fluconazole was withdrawn due to pregnancy, as they believed that
the absence of the trial products would adversely affect their
health. Women from the MDP trial expressed fear of contracting
HIV once they stopped using gel. Many women reported that gel
use was also a means of encouraging negotiation with their regular
sexual partners to use condoms. One woman reported that fellow
participants laughed at her for getting pregnant. As outlined in
section 1, participants in both studies were not concerned about
the effect of investigational products on their pregnancies.
Male partners also expressed regrets about their partner’s
pregnancies whilst on the trial:
‘‘l felt bad when they withdrew gel but when my wife gives birth l will use
the gel again and l will follow instructions’’ Male HIV+ve with female
HIV –ve pregnant partner (MDP).
Views on compulsory directly observed contraception
within trials
During the consent process, the research teams in the trials
emphasized the need for family planning and the different
contraceptives methods available to participants. However, during
this study it emerged that participants did not consider contra-
ception compulsory. When asked if the women would participate
in a trial if they had to use directly observed contraceptives (such as
IUD, Implant or depo injection) as a must the response was mixed:
‘‘For some of us that (compulsory contraception) would have destroyed
our homes since we have just married and people would start asking what has
caused a delay in getting pregnant, and they would say the man wasted his
time, and he could end up getting children elsewhere’’ Female HIV –ve
completed pregnancy (MDP).
‘‘For me l would have joined because I already have children’’ Female
HIV –ve completed pregnancy (MDP).
Discussion
Recent experience in HIV clinical trials in Sub Saharan Africa
has shown that many women get pregnant whilst in a clinical trial.
This has raised anxiety in researchers that there is a failure of
consent, and that trial participants do not fully understand the
importance of avoiding pregnancy. Whilst some of the increased
rates may be due to earlier diagnosis of pregnancy of both viable
and non-viable pregnancies in clinical trials compared to routine
care (due to the use of highly sensitive pregnancy tests and more
regular visits), but this alone does not adequately explain the high
pregnancy rates [17,18].
This study aimed to explore issues in women and men in two
different HIV related trials run concurrently in the same part of
Uganda. One was a prevention trial with both male and female,
HIV negative and positive participants. The other study was an
HIV intervention study with all HIV positive participants. One
trial was using a novel product and one using a widely used
licensed drug in a novel manner. By gathering information from
participants and their partners in two different trials we were
attempting to see what general similarities exist around reasons
for pregnancy in different research settings in order to help us
plan future HIV trials in Uganda which address the contracep-
tive needs and fertility desires of participants as much as possible.
This was a retrospective study so inherently open to bias. We
tried to avoid this by choosing of a wide range of different focus
group participants. Given the sensitive nature of contraception
and pregnancy issues the choice members for each focus groups
was designed to maximize the comfort level of the participants
(by separating the women into pregnant, non-pregnant and those
who had completed their pregnancy) as it was important to try to
make the participants of each group as open with each other as
possible. The thoughts and desires of men have not been studied
in this context, and including male partners was an attempt to
get a full picture of decisions that couples make regarding fertility
in clinical trials.
We found that the consent processes seemed to be effective in
both trials; the participants acknowledged that they had received
counselling and consent about adverse or unknown effects of trial
product on a pregnancy. However, there was a general lack of
concern about the drug affecting the pregnancy; only one mother
was concerned about trial drug after giving birth to a low birth
weight baby. This is an area we feel that warrants further
exploration; is there a cultural belief in Uganda that in general
drugs do not harm the unborn child? In diaphragm and gel study
in South Africa there was a strong positive feeling towards
investigational products in terms of enhanced sexual pleasure and
product protection against HIV’’[19]. Therefore, perhaps this is
part of a positive belief around investigational products ‘‘preven-
tion method optimism’’ as termed by Van der Straten during work
in Zimbabwe with the diaphragm as STI prevention [20]. As a
result of this we feel that whilst discussions and questionnaires to
assess understanding of a research trial may be adequate for most
trials, exploration of alternative methods for informed consent
evaluation, such as vignette or narratives, as evaluated for HIV
vaccine studies in Sub Saharan Africa [21], could be considered in
cases where there is a high risk of foetal abnormality or risk to the
mother if she becomes pregnant.
Motivation for enrolling in a clinical trial may be multiple and
complex. Studies have shown that there may be a desire to get
access to improved health care, access to HIV testing or a desire to
help the community. In the MDP study protection against HIV
transmission for a discordant couple was strong. Occasionally the
motivation is financial. Therefore, this may lead to commitment
on the part of the study participant that is difficult to keep [22–24].
In our study the couple who planned for pregnancy whilst taking
part in the MDP trial is an interesting example of this; further
exploration of their motivation for joining the trial may have been
insightful.
Homsy and colleagues [7] concluded that women and their
partners need to be offered regular and comprehensive family
planning services as part of their standard package of care to
reduce on unwanted/unplanned pregnancies. A randomized
intervention looking at pregnancy and HIV/STD risk reduction
suggested partner support for contraception may assist in reducing
unwanted pregnancy [25]. However, concerns about health and
side effects of contraception were expressed strongly by both HIV
positive and negative women in this study, and this is in line with
other published data suggesting that around 23% of women in
Sub-Saharan Africa are not accessing contraception because they
are concerned about the health and side effects of contraception
[26]. Readily available contraceptive options in this setting are
hormonal contraceptives (oral, injectable and implants methods)
and non-hormonal methods (IUD and condoms). There is some
evidence that African women desire to see a menstrual period, and
may be equivocal about injectable and implant hormonal
contraceptive use [27]. However, young women in South Africa
report high levels on hormonal contraceptive use (66.6%) [28] and
the use of injectable contraception is rapidly increasing across the
continent [29,30] (albeit with high discontinuation rates of 25–
36% within the first year, due to side effects or wanting to get
pregnant). Participants in an HIV vaccine trial in East Africa
showed a greater uptake of injectable contraception (34%) as
Pregnancy in HIV Clinical Trials in Africa
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compared to other hormonal contraception (24.3%) [31]. An HIV
prevention trial focusing on diaphragm and lubricant gel use
highlighted the advantages of female initiated non hormonal
contraception, and whilst not currently commonly used in Africa,
this work highlights that the diaphragm is worth exploring as
alternative method [19].
Ethically, trials that involve investigational products with any
possibility of foetal abnormality undertaken in women of
childbearing age require protection of the participants against
pregnancy. Condom use is increasing in SSA [32], and some
microbicide trials have shown high uptake (99%) [33]. Our work
shows a reluctance of some men to use condoms consistently, even
when they are in a trial and in a discordant relationship. We also
know that they are not 100% effective at preventing pregnancy. In
addition there is concern over increased HIV transmission and
acquisition with hormonal contraception [12], and current WHO
guidance is to advise condoms when using hormonal contracep-
tion. Hormonal contraceptive and antiretroviral therapy have
complex drug interactions. Therefore, we feel that the ethical
obligation on the part of researchers to offer condoms plus an
additional contraception (ideally chosen by the woman) is
appropriate. Given varying cultural contexts and different fertility
desires of women, a range of contraceptive options should be
available. However, there also needs to be an adequate
explanation of the different contraceptive methods offered, with
the efficacy and safety profiles in the context of HIV outlined to
potential participants.
Finally, it is clear that men also have a role to play in the
deciding if a couple gets pregnant. In some circumstances there is
also pressure from other family members. HIV clinical trials often
recruit women of childbearing age, and participants are often
followed up for long periods of time. Perhaps it is unrealistic to ask
couples of child bearing age to avoid pregnancy for long periods
either in HIV prevention studies when the women may well be
HIV negative, or in HIV treatment trials where the women are
accessing ART which improves their health. Researchers need to
acknowledge this, and encourage an open discussion with
participants about contraception and fertility needs; far better a
women withdraws from a study with knowledge of researchers,
than discontinues trial product use, as we have seen in microbicide
trials in South Africa [34].
Given current efficacy and safety issues with different contra-
ception methods in the context of HIV, consent for clinical trials
involving HIV positive participants should carefully address these
complex contraception issues in order to make sure that
participants understand all of the different issues related to
hormonal and non-hormonal contraception in this environment.
Conclusion
Individuals and couples in these trials made decisions to become
pregnant despite acknowledging that they received information
about risks during the informed consent process. A couple’s desire
for children changes over time, and with changes in health,
financial and relationship status. Researchers and scientists need to
take this into account when planning trials in regions with high
fertility rates. The level of risk to a pregnancy of investigational
products in trials recruiting women of childbearing age needs to be
assessed and discussed in ethics committees; with increased
contraception options (inclusion of the diaphragm for example),
and perhaps a separate consent form for women which more fully
explores contraceptive choices (with efficacy and safety). As
researchers we need to be realistic about the limitations of
informed consent when it comes to something as fluid and
complex as the desire, and capacity of a couple to have children;
for very high risk products, perhaps a review of informed consent
and pregnancy desires on an annual basis should be considered.
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